In conventional bioassays, isolated cells are suspended in culture media, incubated in vitro for several days, and then characterized with respect to any cellular changes. In developing new molecular tests under physiological ex vivo conditions, we quantified the production of mRNAs for p21 and PUMA (p53 upregulated modulator of apoptosis), which are involved in cell cycle arrest and apoptosis, respectively.
Personalized, or individualized, medicine is a new concept for identifying the suitable treatment for each patient (1 ) . This approach is particularly important for cancer patients, because chemotherapeutic agents are known to induce severe side effects. When a diagnosis is made, drug regimens are generally selected on the basis of the type and characteristics of the cancer cells without testing their sensitivity to the drugs in vitro, and the patients undergo a standard treatment that has been validated statistically. Although the initial induction therapy works in many cases, the identification of suitable drugs becomes critically important when disease relapse occurs.
The sequence variation (single-nucleotide polymorphism) in the genomic DNA responsible for drug metabolism has been extensively studied recently, and these data have been used to predict which patients will not respond to particular drugs (2 ) . Such information is not available for all drugs, however, and although it may predict nonresponders with altered drug metabolism, this approach is not immediately applicable for identifying the drugs that would be effective in particular patients. Furthermore, whether a second or third yet-to-be-identified single-nucleotide polymorphism would compromise or accelerate the drug response is not known.
Microarray technologies have also been used to predict drug responses by enabling the characterization of the expression of thousands of genes in cancer cells to find patterns that distinguish drug responders from nonresponders (3 ) . Creating such a profile is a difficult task, however, and the available data are limited. Furthermore, once specific patterns are identified, it is still difficult to understand how the expression of each gene is involved in a particular drug response. The quality control of thousand of spots in microarray chips is yet another challenge.
In the case of leukemia and lymphoma, the cancer cells exist in the peripheral blood. Because many drugs are administered intravenously and their blood concentrations can be quantified, in vitro simulation is feasible by incubating samples of whole blood with each drug under consideration. In the in vitro tests of drug sensitivity that have previously been used to identify appropriate drugs (4 ), leukemic cells were isolated, suspended in artificial culture media, and incubated with the drug in vitro for 48 h to characterize any cell damage; however, a drug-sensitivity test is not commonly available for leukemia, because of various technical difficulties and the discrepancies that have been observed between laboratory results and clinical outcomes.
We recently found that mRNAs for p21 and PUMA 4 (p53 up-regulated modulator of apoptosis) were the most predictive mRNA markers of leukocyte apoptosis (5 ) and that the induction of these mRNAs was detectable in human whole blood within 1-4 h of drug incubation (5 ) . p21 is an inhibitor of cyclindependent kinase (6 ) , and increased p21 production consequently causes cell cycle arrest (7 ) . p53 induces the production of mRNA for PUMA (8 ) , which liberates BAX to promote apoptosis (9 ) . Thus, analysis of the expression of the genes encoding these 2 proteins may reveal an association with the cytostatic and cytocidal effects of drugs, similar to the bacteriostatic and bacteriocidal effects of antibiotics. In this second in a series of investigations on the clinical applications of the mRNA technology we have developed (10, 11 ) , we reinvestigated the concept of drug-sensitivity testing with new molecular tests carried out under physiological ex vivo conditions.
Materials and Methods

BLOOD SAMPLING
Heparinized samples of whole blood were obtained from Hitachi, Ltd., Hitachi General Hospital (Hitachi, Japan), and the Apex Research Institute (Tustin, CA) after approval by the respective institutional review boards. The 40 healthy adult volunteers of Japanese descent used in this study consisted of 10 participants each with ages in the twenties, thirties, forties, and fifties; there were equal numbers of men and women. We also obtained blood samples from 30 healthy adults and 18 patients with various blood malignancies [acute myelogenous leukemia (AML), 8 patients; chronic lymphocytic leukemia, 4 patients; acute lymphocytic leukemia, 3 patients; non-Hodgkin lymphoma, 2 patients; and myelodysplasia, 1 patient] in order to optimize assay conditions during preliminary studies (data not shown). We then studied a new set of 18 AML patients (12 men and 6 women, 30 -86 years of age; 17 new cases and 1 relapse case), including 4 cases of acute promyelocytic leukemia. Blood was drawn from these 18 AML patients before chemotherapy, stored at 4°C, and stimulated with the appropriate drugs on the same day. Blood samples were processed for mRNA analysis after each drug-stimulation treatment.
PRIMERS AND PROBES
PCR primers and TaqMan probes were designed with Primer Express (Applied Biosystems) and HYBsimulator (RNAture), as previously described (7 ) . Oligonucleotides were synthesized by Integrated DNA Technologies, Tsukuba Oligo Service, Nippon EGT, and Hokkaido System Science. 
mRNA QUANTIFICATION
Absolute mRNA concentrations (copies/microliter blood) were measured by assessing mRNA recovery and cDNA-synthesis efficiency in each sample, as previously described (10, 11 ) . Each gene was amplified individually. The cycle threshold (Ct), the PCR cycle that generated certain amounts of PCR products (as measured by fluorescence), was evaluated with SDS analytical software (Applied Biosystems). We used 10 -10 6 copies/well of calibrator templates in each PCR for calibration. The Ct values for the external control, RNA34, were converted to copy numbers, and percent recovery was calculated for each well (10, 11 ) . For p21 and PUMA, we used the respective calibration curves to convert Ct values to copy numbers and then converted copy numbers to copies/microliter of blood by dividing by percent RNA34 recovery in each sample, according to the method we reported previously (10 ) . We divided each copy number obtained for triplicate drug-treated samples by the mean copy number of the control samples to calculate the mean (SD) values for the fold increase. The Student t-test was used for statistical analyses.
NUCLEOSOME ANALYSIS
We incubated blood samples from 10 AML patients overnight with the drugs and then used a sandwich immunoassay (Cell Death Detection ELISA PLUS reagent set; Roche Diagnostics) to quantify the amounts of nucleosome, one of the end products of apoptosis. In brief, we mixed 5-L samples of whole blood with 200 L of Lysis Buffer supplied in the reagent set and incubated them at room temperature for 30 min. After centrifugation at 10 000g for 10 min, we mixed 20 L of supernatant with 80 L of ImmunoMix, which contains biotin-labeled mouse monoclonal antibody against human histone and peroxidase-labeled mouse monoclonal antibody against human DNA, and transferred this mixture to streptavidin-coated 96-well microplates. After a 2-h incubation at 37°C, the microplates were washed 3 times with the Incubation Buffer supplied with the reagent set. We then added 100 L of substrate solution [2,2Ј-azino-bis(3-ethylbenzthiazoline-6-sulfonate), ABTS] to each well and incubated the microplates at room temperature for approximately 20 min. We then measured the absorbance at 405 nm and 490 nm with an ARVO microplate reader (PerkinElmer). The enrichment factor was calculated by dividing the values for the drug-treated samples with those for the vehicle-treated (PBS or DMSO) control samples.
ANNEXIN V ANALYSIS
We incubated 70-L samples of blood from 5 AML patients overnight with the drug and then added 630 L VersaLyse (Beckman Coulter) to lyse erythrocytes. After centrifugation at 400g for 5 min, we suspended the leukocytes in 490 L Binding Buffer and incubated the leukocyte suspension with 5 L each of fluorescein isothiocyanate-labeled annexin V and propidium iodide (BioVision) at room temperature for 5 min in the dark. We then incubated the suspension on ice for an additional 10 min with 20 L of phycoerythrin-labeled antihuman CD45 monoclonal antibody (Beckman Coulter). We then analyzed annexin V binding via flow cytometry (EPICS XL-MCL; Beckman Coulter) with CD45 gating [excitation, 385 nm (argon laser); emission, 525 nm (for phycoerythrin)] and side scatter and monitored the emission signals at 488 nm (fluorescein isothiocyanate) and 675 nm (propidium iodide).
Results
mRNA ASSAY VERSUS CONVENTIONAL APOPTOSIS ASSAYS
We defined a 1.5-fold increase as the cutoff value (Fig. 1, dotted lines) , because the majority of the results stayed below this value in both the nucleosome ELISA and the annexin V fluorescence-activated cell sorting (FACS) analysis. The total numbers of analytical data points (for the various combinations of patients and drugs) for the ELISA and the FACS analysis were 198 and 65, respectively. As shown in Fig. 1 (lower-left quadrant in each graph), the lack of mRNA responses for p21 (Fig. 1 , A and C) or PUMA (Fig. 1 , B and D) (x-axis, Ͻ1.5-fold increase) corresponded with the lack of responses in the ELISA (Fig. 1, A and B ) and the FACS analysis (Fig. 1 , C and D) (y-axis, Ͻ1.5-fold increase) in 65%-70% of the cases. Seven percent of the p21 data points and 6% of the PUMA data points showed dual positive results in both the mRNA analysis and the ELISA (Fig. 1, A and B, upper-right quadrant), and the frequencies of such dual positives were 15% for the mRNA and FACS analyses for both p21 and PUMA (Fig. 1, C and D, upper-right quadrant). Only 2%-3% of the results were positive in the ELISA or the FACS analysis without any mRNA response (Fig. 1 , upperleft quadrant), whereas 15%-26% of the data points consisted of positive mRNA responses (p21 or PUMA) without positive results in the ELISA or the FACS analysis (Fig. 1, lower-right quadrant) .
DRUG-INDUCED p21 AND PUMA mRNA IN AML AND CONTROLS
The results for 40 healthy adult volunteers and 18 AML patients are summarized in Fig. 2 . AraC and DNR induced significantly lower p21 and PUMA mRNA responses in AML cases (Fig. 2, D and E) than in control samples (Fig. 2, A and B) (all P Ͻ0.0001), although 17 of the AML patients had never been exposed to chemotherapeutic drugs. The dual-negative population was increased for both p21 and PUMA, from 10% to 56% for AraC (Fig. 2, A and D, lower-left quadrant) and from 15% to 39% for DNR (Fig. 2, B and E, lower-left quadrant). Contrasting results were obtained for IDR (Fig. 2, C and F) , and AML samples showed significantly higher responses than controls (P ϭ 0.01 for both p21 and PUMA). The dual-negative population decreased from 13% to 6% (Fig. 2, C and F, lower-left quadrant). One relapse case (Fig. 2, D-F, arrow) showed results similar to those of other AML cases.
As shown in Fig. 3A (upper-left quadrant), 28% (p21) and 39% (PUMA) of patients had positive re-sponses (Ͼ2-fold increase) to DNR and a lack of response to AraC, whereas only 11% (p21) and 0% (PUMA) of patients had positive responses to AraC and a lack of response to DNR (lower-right quadrant). Positive responses to IDR were seen in patients with a lack of response to DNR (Fig. 3B , lower-right quadrant) and AraC (Fig. 3C, lower-right quadrant) , whereas we found no case of a positive response to DNR or AraC with a lack of response to IDR (Fig. 3, B and C, upper-left quadrant).
EFFECT OF PSL
Among the 108 data points (i.e., 6 drugs ϫ 18 patients), PSL did not enhance or inhibit the induction of p21 and PUMA mRNA by any drug, with the exception of the 3 cases shown in Fig. 4 . Although stimulation with PSL alone and with the drug alone produced no change compared with the PBS control values, costimulation with PSL plus MIT (Fig. 4A) or PSL plus AraC (Fig. 4 , B and C) significantly induced p21 mRNA (Fig. 4 , open columns) and PUMA mRNA (Fig. 4B, closed columns) .
INDIVIDUAL PATTERNS OF DRUG RESPONSES
Individuals differed with respect to their responses to the various drugs, but these responses could be categorized into 4 patterns. As shown in Fig. 5A , 22% of AML cases showed positive responses to both AraC and DNR and not to ACR. Another 22% showed positive Blood samples from 10 (A, B) or 5 (C, D) AML patients were stimulated with various drugs for 4 h. We then quantified p21 (A, C ) and PUMA (B, D) mRNAs and calculated the fold increase in mRNA concentration (x-axis), as described in Materials and Methods. The remainder of the blood samples were further incubated overnight, and ELISA and FACS analysis were used to quantify nucleosome (A, B; y-axis) and annexin V (C, D; y-axis), respectively. Dotted lines represent the cutoff value of a 1.5-fold increase. The numbers of data points (various combinations of patients and drugs) for the ELISA and the FACS analysis were 198 and 65, respectively.
Fig. 2. Induction of p21 and PUMA mRNAs in healthy adult control individuals and AML patients.
Blood samples were stimulated with 10 mol/L AraC (A, D), 2 mol/L DNR (B, E), or 2 mol/L IDR (C, F ) for 4 h. We then quantified p21 (x-axis) and PUMA (y-axis) mRNAs and calculated the fold increase in mRNA concentration, as described in Materials and Methods. (A-C), Healthy adult volunteers (n ϭ 40; 10 each with ages in the twenties, thirties, forties, and fifties, with equal numbers of males and females). (D-F), AML patients (n ϭ 18). Dotted lines represent the cutoff of a 1.5-fold increase.
Fig. 3. Drug-to-drug analysis.
The same AML data from Fig. 2 were replotted onto x-y plots with AraC data on the x-axis vs DNR data on the y-axis (A), IDR data on the x-axis vs DNR data on the y-axis (B), and IDR data on the x-axis vs AraC data on the y-axis (C). E, p21 mRNA data; OE, PUMA mRNA data.
Ex Vivo Drug-Sensitivity Tests for Leukemia
responses to AraC, DNR, and ACR (Fig. 5B) . Two cases (11%) showed positive responses to DNR and ACR and no response to AraC (Fig. 5C ). Three cases (17%) showed no responses to AraC, DNR, and ACR (Fig. 5D) .
CASE STUDIES
Of the 18 AML cases, 13 cases (15 treatments) were eligible for further analysis. The drugs used clinically were all tested by ex vivo mRNA analysis before chemotherapy, and the clinical follow-up was completed. We also added 4 other cases from our preliminary studies, although some of the information (doses and PUMA response) was missing. All 15 patients who achieved complete remission (CR) had positive mRNA responses to at least one of the drugs (positive match) (Fig. 6, circles) . For 3 cases (2A, 10, and 16; Fig. 6 ) in which the therapy failed to induce a CR, the drugs used clinically all induced no mRNA response (negative match). In case 10, AraC was excluded from the analysis because it had been used clinically at low doses (Fig. 6, hatched box) . Patient 11A used drugs (AraC, DNR, VP-16) that induced a positive mRNA response, but they failed to induce CR, although hematologic improvements were observed (mismatch). A 2 test of the 15 positive matches, 3 negative matches, and 1 mismatch was statistically significant (P Ͻ0.0003). Even when the results of the 4 preliminary cases (14 -17 ) were excluded, the data still showed statistical significance (P ϭ 0.002).
In case 2, AraC and DNR failed to induce CR, and these 2 drugs did not induce an mRNA response (Fig. 6,  patient 2A) . Subsequently, the second treatment regimen consisting of AraC and VP-16 induced CR, and VP-16 induced positive responses for both p21 and PUMA mRNAs (Fig. 6, patient 2B) . In case 11B, therapy with ACR and low-dose AraC (dashed-line box) successfully induced CR. Patients 7 and 8 ( Fig. 6 ) also showed weak p21 mRNA responses to ACR, but these ACR responses corresponded to CRs. Because high doses of AraC and DNR failed to induce p21 and PUMA mRNA responses in case 2, we also analyzed other BAX family mRNAs, as is described in our previous report (5 ) . This study demonstrated that high doses of AraC, DNR, and MIT did not induce apoptosis-related mRNAs (GADD, SUMO, Apaf1, Bfl1, BclII, Bim, Bik, Bid, Bad, Bcl-xs, Bak, and Bax) (data not shown).
Discussion
p21 and PUMA mRNAs are markers of leukocytes' cytostatic and cytocidal functions, respectively. Although the genes encoding these mRNAs are well characterized at the molecular level, this report is the first to describe the use of both p21 and PUMA mRNAs in drug-sensitivity tests for leukemia.
The ex vivo mRNA analyses yielded more positive results than the biological assays (nucleosome ELISA and annexin V FACS) (Fig. 1, lower-right quadrants) . This finding indicates that the mRNA assay may have better analytical sensitivity than these 2 conventional assays, or that it may produce more false-positive reactions. Although biological assays detect actual apoptosis, a finding of apoptosis is not always the gold standard, given that apoptosis may happen artificially during a lengthy in vitro incubation. If antiapoptotic cascades [such as Bcl-2, and so forth (12 ) ] are more dominant than proapoptotic ones or if drug resistance-related proteins such as P-glycoprotein (13 ) are produced in substantial quantities, PUMA induction may not be sufficient to induce apoptosis. Alternatively, post-mRNA cascades may be interrupted artificially or physiologically in whole blood. In contrast, the observation of a lack of mRNA responses along with positive results in biological assays (Fig. 1, upper left quadrants) may be due to direct activation of mitochondria or caspases, or to secondary apoptosis occurring during an overnight incubation. Although we found PUMA mRNA to be the most sensitive apoptosis marker in leukocytes (5 ) and leukemic cells, other Bax family genes or yet-to-be-identified proapoptotic mRNAs may be induced (14 ) . Thus, the results of ex vivo mRNA analyses cannot be ignored because of discrepancy with the results of biological assays.
AraC and DNR induced significantly lower p21 and PUMA mRNA responses in leukemia patients than in healthy controls (P Ͻ0.0001; Fig. 2 ), although patient blood samples were drawn before chemotherapy. Furthermore, these patients (except patient 1 in Fig. 6 ) were new cases and had not received any chemotherapy. The results are not technical artifacts, because the responses to IDR were in the opposite direction (Fig. 2) . The interpretation of the results was straightforward in cases 2 and 6 (Fig. 6) , because the proportion of leukemic blasts in whole blood was Ͼ90% (Fig. 6 ). Although these 2 patients had no response to AraC, the different responses to DNR and IDR suggest variation among the leukemic cells. The patient in case 5 ( Fig. 6 ) had no response to DNR and a very weak response to AraC, whereas the proportion of leukemic cells was only 5% (Fig. 6 ). This finding is not surprising, because such weak responders or nonresponders have been found in healthy adult populations (7 ).
Moreover, nonresponders to one drug were not always resistant to other drugs (Figs. 3, 5, and 6 ). This result is reasonable because in vitro resistance to AraC is generally explained by the inactivation of deoxycytidine kinase, whereas resistance to DNR has been explained as an overproduction of multidrug efflux pumps, such as P-glycoprotein or multidrug-resistance protein (13 ) . Although both DNR and IDR are anthracycline antibiotics, these 2 drugs are not identical in terms of their drug resistance, and verapamil reverses cytotoxicity due to DNR, but not that due to IDR (15 ) . Identification of such discrepancies on an individual basis will be a powerful clinical research tool for the analysis of drug sensitivity and resistance in humans.
In clinical use, many drugs are used in combination (Fig. 6 ). It will be interesting to use such combinations with our method, because the effects of different drugs on these markers may be additive or synergistic. Because our assay system consumes only 50 -70 L of blood per reaction, such analyses are technically feasible. In fact, we analyzed the effects of PSL as the first step (Fig. 4) . Although the majority of the data showed no effect of PSL on drug-induced p21 and PUMA mRNA responses, 3 (2.6%) of 114 data points showed significant enhancement (Fig. 4) . This result indicates that drug responses are not uniform and that interindividual variation exists. High and low doses were used to identify nonresponders and responders, respectively (Fig. 6) . We considered any drug that produced a positive response at low doses and no response at high doses to be possibly toxic; however, we found no such cases. When both high and low doses produced no response, we interpreted the patient to be resistant to the drug, whereas we interpreted double positives as indicating sensitivity to the drug. Interpretation was not straightforward for the cases that showed a positive response at high doses and no response at low doses, however, because we did not know whether the low doses we used (Fig. 6) represented therapeutic doses for each of the patients. Additionally, we did not know the blood concentration of each drug for each patient. In the future, we recommend that appropriate doses be determined empirically through large clinical studies.
Although the number of patients in this study was small, we have obtained valuable information. All of the patients in CR cases received at least one drug that produced a positive mRNA response, and we observed no mRNA responses for clinically used drugs in all cases where such therapy failed to induce any hematologic improvement. This finding indicates that the ex vivo assay may have potential as a drug-sensitivity test. For cases 2, 3, 6, and 9 ( Fig. 6) , ACR may be a candidate drug because the positive p21 responses were similar to those of cases 7, 8, and 11B, although other drugs successfully induced CR. Although the patient in case 5 achieved CR, DNR may be excluded from the therapy because of the weak mRNA responses. Removal of an ineffective drug may reduce the side effects that occur during the chemotherapy and may also decrease costs.
Clinical demand exists for drug-sensitivity tests that can identify the drugs most suitable for each patient. The development of such tests is a large challenge, however. Although the numerous previous attempts have used a wide variety of technologies, none has been accepted as a routine clinical test. This study was a preliminary one, and the number of patients was very small. Moreover, institutional review board restrictions required the study to be a retrospective analysis, not a prospective one; however, this study has successfully introduced the concept of ex vivo mRNA analysis as a candidate platform for drug-sensitivity testing, and this approach has shown sufficient technical and clinical promise for subsequent larger clinical studies. 
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